NASDAQ:LFWD Lifeward Q2 2026 Earnings Report $5.85 -0.11 (-1.85%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$6.03 +0.18 (+3.08%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lifeward EPS ResultsActual EPS-$1.46Consensus EPS -$1.39Beat/MissMissed by -$0.07One Year Ago EPSN/ALifeward Revenue ResultsActual Revenue$6.62 millionExpected Revenue$6.53 millionBeat/MissBeat by +$92.00 thousandYoY Revenue GrowthN/ALifeward Announcement DetailsQuarterQ2 2026Date8/15/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time9:30AM ETUpcoming EarningsLifeward's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lifeward Earnings HeadlinesLifeward Announces Interim CFO Leadership Transition PhaseOctober 1 at 9:10 AM | tipranks.comLifeward (NASDAQ:LFWD) vs. Bioventus (NASDAQ:BVS) Head to Head ContrastSeptember 24, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 4 at 1:00 AM | Porter & Company (Ad)Lifeward Sets Timeline for 2026 Shareholder MeetingSeptember 15, 2026 | tipranks.comLifeward Study Shows ReWalk Exoskeleton Improves Daily Activities, Satisfaction And PainSeptember 15, 2026 | rttnews.comPeer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and PainSeptember 15, 2026 | finance.yahoo.comSee More Lifeward Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lifeward? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lifeward and other key companies, straight to your email. Email Address About LifewardLifeward (NASDAQ:LFWD), formerly known as ReWalk Robotics Ltd., is a medical-device company focused on developing and commercializing wearable robotic systems that help people with mobility impairments stand and walk. Its technologies are designed for individuals with spinal cord injury and other neurological conditions, as well as rehabilitation providers seeking advanced gait-training tools. The company’s principal product is the ReWalk Personal Exoskeleton, a powered wearable robotic system that uses motorized joints, sensors and a computerized control system to support assisted standing and walking. Lifeward has also developed the ReStore soft exosuit, a rehabilitation device designed to provide powered assistance during walking therapy for people recovering from stroke and other conditions affecting mobility. Founded as ReWalk Robotics, the company changed its corporate name to Lifeward in 2024 to reflect a broader focus on mobility and rehabilitation. Lifeward serves healthcare providers and patients through markets that include the United States, Europe and Israel. The company is headquartered in Yokneam, Israel, and has been associated with longtime chief executive Larry Jasinski.View Lifeward ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestMcDonald's Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
